TRAILR4/TNFRSF10D/DcR2 Antibody - BSA Free NBP1-76985 from Novus Biologicals, a Bio-Techne Brand

Product Specs
ItemTRAILR4/TNFRSF10D/DcR2 Antibody - BSA Free
CompanyNovus Biologicals, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberNBP1-76985
FormatPBS
ApplicationsWestern Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Flow (Cell Surface)
Quantity0.1 mg (also 0.025 mg)
Conjugate/TagUnconjugated
ImmunogenAntibody was raised against a 15 amino acid peptide near the center of human DcR2. The immunogen is located within amino acids 230 - 280 of DcR2. Amino Acid Squence: GGPERVHRVLFRRRS
ReactivityHuman, Mouse, Rat
TargetTRAILR4/TNFRSF10D/DcR2
HostRabbit
Concentration1 mg/ml
Brand/TrademarkNovus Biologicals, a Bio-Techne Brand
ClonalityPolyclonal
PurityPeptide affinity purified
Research AreaApoptosis, Cancer, Cell Biology, Cytokine Research, Immunology, Innate Immunity
Molecular Weight36 kDa
IsotypeIgG
NCBI Full Gene NameTNF receptor superfamily member 10d
NCBI Gene AliasesTRAILR4, CD264, DCR2, TRUNDD, TRAIL-R4
Antibody TypePrimary Antibodies
StorageStore at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles

Specifications/Features

Available conjugates: Unconjugated

Add to Compare List

Novus Biologicals, a Bio-Techne Brand

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

Company Profile

Website: http://www.novusbio.com

(1) HIF-1α Mediates TRAIL-Induced Neuronal Apoptosis via Regulating DcR1 Expression Following Traumatic Brain InjuryFrontiers in cellular neuroscienceJanuary 1, 2020Fang Y, Lu J, Wang X, Wu H, Mei S, Zheng J, Xu S, Lenahan C, Chen S, Zhang J, et al.(1:1,000, Abcam, Waltham, MA, USA, ab133658), anti-DcR2 antibody (1:1,000, Novus, St Charles, MO, USA, NBP1-76985), anti-HIF-1α antibody (1:500, Abcam, Cambridge, MA, USA, ab2185), anti-caspase-3 antibody (1:1,000,

(2) Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathwayThe Journal of biological chemistryNovember 8, 2013Gupta SC, Francis SK, Nair MS, Mo YY, Aggarwal BB.

(3) Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesMolecular cancer therapeuticsOctober 1, 2012Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS.

(4) Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivoNeuro-oncologyJuly 1, 2010Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y.

(5) Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cellsCancer researchNovember 1, 2008Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T, Sakai T.

(6) Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathwaysBloodSeptember 15, 2008Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, et al.

(7) Regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by DJ-1 in thyroid cancer cellsEndocrine-related cancerJune 1, 2008Zhang HY, Wang HQ, Liu HM, Guan Y, Du ZX.

(8) Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surfaceCancer researchNovember 15, 2007Kawakubo T, Okamoto K, Iwata J, Shin M, Okamoto Y, Yasukochi A, Nakayama KI, Kadowaki T, Tsukuba T, Yamamoto K.

(9) Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivityCancer researchOctober 15, 2005Liu X, Yue P, Khuri FR, Sun SY.

(10) Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivoCancer chemotherapy and pharmacologyFebruary 1, 2005Fan QL, Zou WY, Song LH, Wei W.

(11) Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencingInvestigative ophthalmology & visual scienceJanuary 1, 2005Poulaki V, Mitsiades CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, Halikias IX, Voutsinas G, Tseleni-Balafouta S, Miller JW, et al.

(12) Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritisJournal of gastroenterology and hepatologyJuly 1, 2003Koyama S.

(13) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsOncogeneAugust 22, 2002Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, et al.

(14) Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cellsThe American journal of pathologyAugust 1, 2002Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N.

(15) Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cellsBloodMarch 15, 2002Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.

(16) Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumorJournal of cancer research and clinical oncologyFebruary 1, 2002Koyama S, Koike N, Adachi S.

(17) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applicationsBloodAugust 1, 2001Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.

(18) The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoproteinThe Journal of biological chemistryJune 22, 2001Basile JR, Zacny V, Münger K.

(19) Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5Cancer researchMarch 15, 2001Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.

(20) Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligandCancer researchAugust 1, 2000Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I.

Be the First to Write a Review!

Frontiers in cellular neuroscience

Frontiers in cellular neuroscience

TRAILR4/TNFRSF10D/DcR2 Antibody - BSA Free from Novus Biologicals, a Bio-Techne Brand

Specifications/Features

Novus Biologicals, a Bio-Techne Brand

Citations (20)

Reviews

TRAILR4/TNFRSF10D/DcR2 Antibody - BSA Free from Novus Biologicals, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map